Evidence map›Paper›PMID 42004056›Full record

ArticleAmerican journal of cancer research2026

Precision chemotherapy duration in advanced ovarian cancer: neoadjuvant cycle optimization and differential treatment adaptation by cytoreduction outcome.

Wan-Ting Lin, Chen-Hsuan Wu, Hao Lin, Yu-Che Ou, Hung-Chun Fu, Ching-Chou Tsai, Ying-Wen Wang, Szu-Wei Huang, Ying-Yi Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wan-Ting LinDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Chen-Hsuan WuDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Hao LinDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Yu-Che OuDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Hung-Chun FuDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Ching-Chou TsaiDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Ying-Wen WangDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Szu-Wei HuangDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.
Ying-Yi ChenDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung 833, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective study evaluated the impact of neoadjuvant chemotherapy (NACT) cycle number and total chemotherapy (TCT) cycle number on survival and surgical outcomes in patients with advanced epithelial ovarian cancer undergoing interval debulking surgery (IDS). A total of 115 patients with FIGO stage III-IV ovarian cancer treated with NACT followed by IDS were included and categorized by NACT cycle number (2-4 vs. ≥ 5) and TCT cycle number (≤ 9 vs. > 9). The number of NACT cycles showed no significant association with progression-free survival (PFS, 19.0 vs. 23.0 months, HR = 0.780, 95% CI [0.457-1.332],

Indexed as

adjuvantchemotherapycytoreduction surgical proceduresneoadjuvant therapyOvarian neoplasmstreatment outcome

Identifiers

PMID42004056
PMCPMC13090502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.